Cedric Francois is Chief Executive Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 313,662 shares of APLS, which is worth approximately $10.4 Million. The most recent transaction as insider was on Feb 27, 2023, when has been sold 100,000 shares (Common Stock) at a price of $3.76 per share, resulting in proceeds of $376,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 314K
0% 3M change
16.32% 12M change
Total Value Held $10.4 Million

Cedric Francois Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 27 2023
BUY
Exercise of conversion of derivative security
$376,000 $3.76 p/Share
100,000 Added 8.03%
1,144,591 Common Stock
Feb 21 2023
SELL
Payment of exercise price or tax liability
$93,717 $58.5 p/Share
1,602 Reduced 0.15%
1,044,591 Common Stock
Feb 21 2023
BUY
Grant, award, or other acquisition
-
13,908 Added 1.31%
1,046,193 Common Stock
Feb 10 2023
SELL
Payment of exercise price or tax liability
$202,689 $51.21 p/Share
3,958 Reduced 0.38%
1,032,285 Common Stock
Jan 27 2023
SELL
Payment of exercise price or tax liability
$151,924 $52.77 p/Share
2,879 Reduced 0.28%
1,036,243 Common Stock
Jan 20 2023
SELL
Payment of exercise price or tax liability
$492,028 $52.05 p/Share
9,453 Reduced 0.9%
1,039,122 Common Stock
Jan 12 2023
BUY
Grant, award, or other acquisition
-
83,447 Added 7.37%
1,048,575 Common Stock
Dec 19 2022
SELL
Open market or private sale
$1,466,964 $52.02 p/Share
28,200 Reduced 2.84%
965,128 Common Stock
Dec 19 2022
BUY
Exercise of conversion of derivative security
$355,701 $7.13 p/Share
49,888 Added 4.78%
993,328 Common Stock
Apr 25 2022
SELL
Other acquisition or disposition
-
12,500 Reduced 1.31%
943,440 Common Stock
Feb 10 2022
SELL
Payment of exercise price or tax liability
$118,884 $47.12 p/Share
2,523 Reduced 0.26%
955,940 Common Stock
Jan 28 2022
SELL
Payment of exercise price or tax liability
$78,106 $38.59 p/Share
2,024 Reduced 0.15%
1,338,463 Common Stock
Jan 21 2022
BUY
Grant, award, or other acquisition
-
106,244 Added 7.34%
1,340,487 Common Stock
Jul 21 2021
BUY
Exercise of conversion of derivative security
$62,107 $4.31 p/Share
14,410 Added 1.15%
1,234,243 Common Stock
Feb 10 2021
SELL
Payment of exercise price or tax liability
$120,398 $47.72 p/Share
2,523 Reduced 0.21%
1,219,833 Common Stock
Jan 28 2021
BUY
Grant, award, or other acquisition
-
37,500 Added 2.98%
1,222,356 Common Stock
Jan 27 2021
BUY
Exercise of conversion of derivative security
$289,979 $4.04 p/Share
71,777 Added 5.71%
1,184,856 Common Stock
Dec 15 2020
SELL
Open market or private sale
$260,800 $52.16 p/Share
5,000 Reduced 0.45%
1,113,079 Common Stock
Dec 01 2020
BUY
Exercise of conversion of derivative security
$150,400 $3.76 p/Share
40,000 Added 3.45%
1,118,079 Common Stock
Nov 16 2020
SELL
Open market or private sale
$196,900 $39.38 p/Share
5,000 Reduced 0.46%
1,078,079 Common Stock
Oct 15 2020
SELL
Open market or private sale
$172,300 $34.46 p/Share
5,000 Reduced 0.46%
1,083,079 Common Stock
CF

Cedric Francois

Chief Executive Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS